Stocktwits on MSN
NTLA stock surges 35% overnight: Retail mood peaks ahead of first-ever phase 3 readout for gene-editing therapy
The Haelo Phase 3 trial marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. ・Earlier mid-stage studies showed a 96% reduction in monthly attack rates, with 97% of patients ...
Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results